Objective:To investigate the effects of Bushen Quyu Huoxue decoction on the renal function and blood lipid in patients with chronic glomerulonephritis.Methods:It was a prospective study. A total of 96 cases of chronic glomerulonephritis were selected from The People's Hospital of Linqing from July 2019 to July 2021, and they were divided into a control group (48 cases) and an experimental group (48 cases) with the random number table method. There were 25 males and 23 females in the control group, aged (49.67±8.52) years; there were 26 males and 22 females in the experimental group, aged (49.53±8.67) years. Both groups were given routine treatment, the control group was given losartan treatment, and the experimental group was given Bushen Quyu Huoxue decoction on the basis of the control group. The two groups received continuous treatment for 6 months. The clinical effect, renal function, blood lipid level, and adverse reactions during the treatment were compared between the two groups. Independent sample t test was used for inter-group comparison of the measurement data, paired t test was used for intra-group comparison of the measurement data, and χ2 test was used for the count data. Results:After treatment, the total clinical effective rate of the experimental group was higher than that of the control group [93.75% (45/48) vs. 79.17% (38/48)], with a statistically significant difference ( χ2=4.360, P=0.037). After treatment, the levels of serum creatinine (Scr), urea nitrogen (BUN), 24 h urine protein quantification (24 h UP), triglyceride (TG), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C) in the experimental group were lower than those in the control group [(89.46±10.34) μmol/L vs. (125.35±14.18) μmol/L, (3.27±0.52) mmol/L vs. (6.58±0.75) mmol/L, (0.76±0.12) g/24 h vs. (1.45±0.27) g/24 h, (1.51±0.35) mmol/L vs. (2.13±0.37) mmol/L, (4.83±0.57) mmol/L vs. (6.76±0.75) mmol/L, (1.72±0.24) mmol/L vs. (3.15±0.45) mmol/L], with statistically significant differences (all P<0.001). After treatment, the glomerular filtration rates (GFR) and serum high density lipoprotein cholesterol (HDL-C) levels in the two groups were increased compared with those before treatment, and the GFR and HDL-C in the experimental group were higher than those in the control group [(91.18±6.16) ml/(min?1.73 m 2) vs. (75.35±9.74) ml/(min?1.73 m 2), (1.48±0.25) mmol/L vs. (1.16±0.23) mmol/L], with statistically significant differences (all P<0.001). No serious adverse reactions were observed in the two groups during the treatment. Conclusion:Bushen Quyu Huoxue decoction can effectively relieve the clinical symptoms in patients with chronic glomerulonephritis, improve their renal function, and regulate the blood lipid level, with a significant effect.

目的 研究复方阿嗪米特用于老年功能性消化不良治疗的临床效果.方法 选取2017年5月开始在笔者所在医院消化内科接诊的180例老年功能性消化不良患者为对象,时间截止到2019年11月,分为复方阿嗪米特组与多潘立酮组.查看疗效、不良反应并进行对比.结果 通过医生的医治,复方阿嗪米特组总有效率为96.67％;多潘立酮组总有效率为71.11％.经过医师4周的用药医治后发现,复方阿嗪米特组5.56％的不良反应发生率,2例患者出现恶心,2例出现呕吐,1例出现腹胀;多潘立酮组8.89％的不良反应发生率,有2例出现头疼感觉的患者,4例患者出现心律失常的症状,1例患者出现皮肤瘙痒症状,1例患者出现月经失调症状.多潘立酮组的不良反应发生率明显多于复方阿嗪米特组.结论 复方阿嗪米特治疗老年功能性消化不良具有较好的效果,对老人年的生活质量有了明显的提高,可以广泛应用于临床.

目的:探讨加味乌贝散联合三联疗法治疗胃溃疡的临床效果.方法:选择2015年2月～ 2016年2月来我院进行胃溃疡治疗的患者97例作为此次研究对象,将其分成对照组(48例)与观察组(49例).对照组患者采用常规的三联疗法治疗,观察组在对照组的基础上增加乌贝散治疗,比较两组患者胃溃疡治疗效果.结果:治疗1个月后,观察组患者的治疗有效率(47例,95.92％)明显高于对照组患者(32例,66.67％).观察组患者疾病复发率(2例,4.08％)明显低于对照组患者的复发率(8例,16.67％).治疗后,两组患者的尿急、尿频、尿痛症状都有所缓解,症候积分下降较为明显.但是观察组的变化更加明显,两组间比较具有统计学差异(P＜0.05).结论:在对胃溃疡患者进行治疗的过程中,采用乌贝散联合三联法治疗有利于提升患者治疗的有效率,值得在临床借鉴与推广.

Objective:To analyze the prognostic factors of cholangiocarcinoma treated with Gamma knife radiother-apy.Methods:A retrospective analysis of 63 cases of cholangiocarcinoma treated with Gamma knife radiotherapy trea-ted in The Armed Police General Hospital in Beijing from January 2005 to December 2010 was performed.To analyze prognostic factors by Kaplan -Meirer method for single factor analysis and Cox regression model for multi -factor a-nalysis.Results:The results of single factor analysis:The level of CA19 -9,lymph node metastasis,GTV,vascular in-vasion and the clinical TNM staging were related prognostic factors.The results of Cox regression of multi -factor a-nalysis revealled that lymph node metastasis,vascular invasion and clinical TNM staging were the independent prog-nostic factors of cholangiocarcinoma treated with Gamma knife radiotherapy.Conclusion:CA19 -9≥156U /ml,lymph node metastasis,vascular invasion,GTV≥98cc,the higher level of clinical TNM staging of cholangiocarcinoma were poor prognotic factors.The independent prognostic factors of cholangiocarcinoma treated with Gamma knife radiothera-py were vascular invasion,lymph node metastasis and clinical TNMstaging.

目的：观察中西医结合治疗急性非大面积肺栓塞患者的临床效果。方法将72例急性非大面积肺栓塞患者随机分为2组，抗凝组给予单纯常规抗凝治疗，联合组在此基础上加用豁痰祛瘀中药治疗。治疗前后检测2组血栓素B2（TXB2）、同型半胱氨酸（Hcy）、脑钠肽（BNP）、肿瘤坏死因子－α（TNF－α）水平，比较2组疗效。结果2组治疗后3 h、1 d、3 d、7 d、14 d血浆TXB2、Hcy、BNP、TNF－α水平均较治疗前明显降低（P均＜0．05），且联合组治疗后3 h、1 d、3 d血浆TXB2、Hcy、BNP、TNF－α水平均低于抗凝组（P均＜0．05），治疗后7 d联合组血浆TXB2、TNF－α水平仍低于抗凝组（ P均＜0．05），治疗后14 d 2组TXB2、Hcy、BNP、TNF－α水平比较差异均无统计学意义（ P＞0．05）。结论中西医结合治疗急性非大面积肺栓塞可以减轻再灌注损伤，豁痰祛瘀方对急性非大面积肺栓塞患者有保护作用，建议临床推广应用。

功能性消化不良(functional dyspepsia,FD)是临床上最为常见的消化系统疾病之一,30%人群在一生中均出现过消化不良的症状[1].FD的发病率约为30%～50%[2],其病因十分复杂,与胃肠动力障碍、内脏感知异常、胃酸分泌异常及消化不良等有关,其中胃肠动力障碍是FD的重要病因[3].促动力药物(依托必利)是治疗功能性消化不良的主要药物,但由于FD的发病机制是多因素的,单纯促动力治疗效果并不佳.针对不同机制的多药联合应用治疗FD从理论上分析应具有更好的疗效.我们采用依托必利联合复方阿嗪米特治疗FD,并与单用依托必利治疗进行比较,旨在评价该治疗方法治疗FD的临床疗效和应用的安全性.

目的探讨单纯抗凝疗法对次大面积肺栓塞的疗效。方法将次大面积肺血栓栓塞症患者随机分组并分别应用尿激酶+低分子肝素钙及单纯应用低分子肝素钙治疗。结果 2组治疗前后各项指标比较均有显著性差异,2组治疗效果及主要临床指标变化情况比较无显著性差异。2组治疗后出血率比较有显著性差异。2组1 a复发率比较无显著性差异。结论 2种治疗方法疗效较好;抗凝疗法出血事件发生的风险小。

目的观察豁痰祛瘀法治疗急性大面积肺栓塞患者的临床疗效。方法将60例临床急性大面积肺栓塞患者随机分为2组,溶栓组30例行单纯溶栓抗凝,中西医结合组30例在溶栓抗凝基础上加用豁痰祛瘀中药。分别在治疗前及治疗3 h、1 d、3 d、7 d、14 d检测血液中血栓素B2(TXB2)、同型半胱氨酸(HCY)、脑钠肽(BNP)、肿瘤坏死因子α(TNF-α)水平的变化,对2组的疗效进行比较。结果 2组治疗后TXB2、Ho、BNP及TNF-α水平与治疗前比较均有显著性差异(P均<0.05)。治疗后3 h、1 d、3 d 2组血浆TXB2、HCY、BNP、TNF-α水平比较有显著性差异(P均<0.05);治疗后7 d 2组血浆HCY、TNF-α比较有显著性差异(P均<0.05),而TXB2、BNP水平比较无显著性差异(P均>0.05)。结论豁痰祛瘀方对急性大面积肺栓塞患者有一定保护作用,可以临床推广。